Elevance Health (NYSE:ELV – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Thursday. Several other ...

This was the stock's second consecutive day of losses.

Elevance Health (NYSE:ELV) traded higher in the premarket on Tuesday, a move attributed to comments made by the company's CFO Mark Bradley Kaye at the ongoing Barclays Global Healthcare Conference.

Equities researchers at Wolfe Research issued their FY2029 earnings per share (EPS) estimates for Elevance Health in a note issued to investors on Monday, March 31st. Wolfe Research analyst J. Lake ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the ...

Elevance Health (ELV) stock is one of the worst S&P 500 stocks in Thursday's session. The selloff comes after the health insurance company missed bottom-line expectations for its third quarter and ...

Elevance Health remains a buy with its strong fundamentals. An added bonus is its defensive nature during the tariff wars. Regulatory changes under Trump's administration and AI integration are ...

We recently compiled a list of the Top 10 Health Insurance Stocks To Buy. In this article, we are going to take a look at where Elevance Health, Inc. (NYSE:ELV) stands against the other health ...

With a market cap of $102.5 billion, Elevance Health, Inc. (ELV) is a health benefits company offering a wide range of medical, pharmacy, and healthcare services across its four segments: Health ...

Elevance Health (ELV) shares rallied 5.4% in the last trading session to close at $452.69. This move can be attributable to notable volume with a higher number of shares being traded than in a ...